EC Approves Dupilumab for CSU
The European Commission has approved dupilumab (Dupixent, Sanofi & Regeneron) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines (H1AH) and who are naïve to anti- immunoglobulin-E (IgE) therapy for CSU.